



August 15, 2017

## CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in four upcoming investor conferences.

### **Piper Jaffray Bus Tour** in Palo Alto, CA

- | Dr. Peter Maag and Michael Bell will participate on Wednesday, August 23, 2017 at 9:30am PT/12:30pm ET

### **Southern California Investor Conference** in Newport Beach, CA

- | Dr. Peter Maag will present on Thursday, August 24, 2017 at 10:30am PT/1:30pm ET

### **Rodman & Renshaw 19<sup>th</sup> Annual Global Investment Conference** in New York City

- | Dr. Peter Maag will present on Monday, September 11, 2017 at 12:00pm PT/3:00pm ET

### **Cantor Fitzgerald Global Healthcare Conference** in New York City

- | Dr. Peter Maag will present on Tuesday, September 26, 2017 at 12:25pm PT/3:25pm ET

Live audio webcasts of Southern California Investor, Rodman & Renshaw Global Investment and Cantor Fitzgerald Global Health conferences will be available online from the investor relations page of the Company's website at <http://investors.caredxinc.com>. The webcast replays of the presentations will begin approximately one hour after the conclusion of the live presentations and will be available on the Company's website for 90 days. Due to the one-on-one only format of the Piper Jaffray Bus Tour, no webcast will be available.

### **About CareDx**

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: [www.CareDx.com](http://www.CareDx.com).

Investor Contact

Sasha King, Chief Commercial Officer

T: +1 415-287-2393

E: [sking@caredx.com](mailto:sking@caredx.com)

 Primary Logo

Source: CareDx, Inc.

News Provided by Acquire Media